Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Illinois researchers, including some working on vaccines for cancer and rare diseases, worry the federal government turning ...

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna’s EP’949 patent. This decision affirms the ...

With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Moderna (MRNA) stock drops even after beating Q2 2025 forecasts, as it lowered the top end of the revenue outlook due to vaccine shipment delays. Read more here.

While Moderna is certainly enthusiastic about its near-term mRNA prospects, the company’s COVID-19 business is going through an odd patch, which has afflicted pandemic players of all stripes.